Introduction {#art40718-sec-0005}
============

Sacroiliac (SI) joint imaging plays a pivotal role in the process of diagnosing axial spondyloarthritis (SpA) [1](#art40718-bib-0001){ref-type="ref"}. Conventional radiography has been and remains the most commonly used method to detect sacroiliitis. However, radiographic abnormalities evolve over several years, which contributes to a reported delay in diagnosis of 8--9 years [2](#art40718-bib-0002){ref-type="ref"}, [3](#art40718-bib-0003){ref-type="ref"}. This substantial delay is problematic, because effective treatments are available for patients with axial SpA [4](#art40718-bib-0004){ref-type="ref"}, [5](#art40718-bib-0005){ref-type="ref"}, [6](#art40718-bib-0006){ref-type="ref"}. Over the last decade, magnetic resonance imaging (MRI) rapidly gained ground and proved to be an important imaging technique in the diagnosis of (nonradiographic) axial SpA [7](#art40718-bib-0007){ref-type="ref"}. MRI enables the detection of inflammatory sacroiliitis at an early stage, months to years before structural damage can be detected by conventional radiography [8](#art40718-bib-0008){ref-type="ref"}, [9](#art40718-bib-0009){ref-type="ref"}. Besides the fact that MRI has substantial advantages over radiography in terms of sensitivity, it has the benefit of providing information on both activity and structural damage through the use of only one imaging modality [10](#art40718-bib-0010){ref-type="ref"}, [11](#art40718-bib-0011){ref-type="ref"}, [12](#art40718-bib-0012){ref-type="ref"}.

Axial SpA should be considered in patients with chronic back pain who have an age at onset of \<45 years. Regrettably, no formal diagnostic criteria exist, and there is no single SpA feature with sufficient specificity to establish the diagnosis. The modified Berlin algorithm [1](#art40718-bib-0001){ref-type="ref"} is a helpful tool for rheumatologists in establishing an early diagnosis of axial SpA with greater confidence. According to this algorithm, MRI of the SI joints should be performed in some patients after obtaining conventional radiographs and HLA--B27 testing [13](#art40718-bib-0013){ref-type="ref"}. The most recently published European League Against Rheumatism recommendations on imaging in SpA even state that for certain patients, such as young patients and those with short symptom duration periods, MRI of the SI joints is an alternative primary imaging method [14](#art40718-bib-0014){ref-type="ref"}.

Although inflammation detected by MRI is now widely considered to be an important manifestation in early axial SpA, not much evidence is available on how inflammatory lesions develop over time (outside of clinical trials) [15](#art40718-bib-0015){ref-type="ref"}, [16](#art40718-bib-0016){ref-type="ref"}. However, with the increased interest in MRI in the early diagnosis of axial SpA, examining this manifestation is important. We know that inflammatory lesions (e.g., bone marrow edema \[BME\]) can change over relatively short periods of time in patients diagnosed as having SpA, but in patients with chronic back pain and in whom axial SpA is suspected, it is unclear if BME lesions newly develop or fluctuate both in number and in size over time. Therefore, a relevant clinical question is: if an MRI scan is normal but there is still a clinical suspicion of axial SpA, should the MRI be repeated, and if so, after what period of follow‐up? Or does this not impact the diagnostic process? The Spondyloarthritis Caught Early (SPACE) cohort is an ideal cohort to investigate this research question, as it includes a population of patients with back pain of short duration who were referred to rheumatologists with a suspicion of SpA, but without the mandatory presence of single or multiple SpA features. In the present study, we aimed to investigate the evolution of MRI‐detected lesions at 3‐month and 1‐year time points in the SPACE cohort.

Patients and methods {#art40718-sec-0006}
====================

Study design and patient population {#art40718-sec-0008}
-----------------------------------

SPACE is a multinational ongoing cohort study that began in January 2009. Across 5 participating centers in Europe, patients with chronic back pain (duration 3 months--2 years, age ≥16 years, age at onset \<45 years) are included. Before the start of the study, approval was obtained by local medical ethics committees. Before inclusion, written informed consent was obtained from all patients in accordance with the Declaration of Helsinki. A detailed description of the SPACE cohort has been published elsewhere [17](#art40718-bib-0017){ref-type="ref"}. All patients underwent a diagnostic evaluation at baseline, which included a physical examination, MRI and radiographs of the SI joints, HLA--B27 testing, and an examination for all other SpA features [13](#art40718-bib-0013){ref-type="ref"}, [18](#art40718-bib-0018){ref-type="ref"}. Patients fulfilling the Assessment of SpondyloArthritis international Society (ASAS) axial SpA criteria at baseline or patients with possible axial SpA (i.e., the evidence of SpA features \[though not to a sufficient degree to be classified as axial SpA, defined as the presence of ≥1 SpA feature\]) were included for follow‐up visits. At the 3‐month and 1‐year follow‐up visits, clinical and laboratory data were collected, and another MRI of the SI joints was performed. Three‐month MRI data on patients enrolled in the cohort after July 2012 were not included, because it was decided that 3‐month data on \~150 patients were sufficient to make valid conclusions regarding lesion change.

Imaging and scoring methodology {#art40718-sec-0009}
-------------------------------

MRI of the SI joints was performed using a 1.5T scanner at baseline and follow‐up. Coronal oblique MRI images were obtained, with a slice thickness of 4 mm. Both short tau inversion recovery (STIR) and T1‐weighted turbo spin‐echo (T1WSE) sequences were acquired and evaluated in the scoring process. At baseline, conventional radiography of the pelvis (i.e., SI joints) in anteroposterior view was performed. MRI scans and radiographs of the SI joints were scored independently by 2 trained and well‐calibrated readers who were blinded with regard to patient characteristics, clinical data, time sequence, and data from the other imaging modality. In the case of score discrepancies, a third reader scored the images.

Radiographs were marked positive for sacroiliitis according to the modified New York criteria [19](#art40718-bib-0019){ref-type="ref"} (i.e., the presence of bilateral grade 2--4 sacroiliitis and/or unilateral grade 3--4 sacroiliitis). According to the ASAS definition, an MRI scan of the SI joints was recorded as positive if ≥1 BME lesion highly suggestive of SpA was present on ≥2 consecutive slices or if several BME lesions highly suggestive of SpA were visible on a single slice [7](#art40718-bib-0007){ref-type="ref"}, [18](#art40718-bib-0018){ref-type="ref"}. MRI scans were also scored according to the Spondyloarthritis Research Consortium of Canada (SPARCC) system, which measures inflammation on a continuous scale (0--72) [20](#art40718-bib-0020){ref-type="ref"}. According to the SPARCC score, the presence of an increased signal corresponding to BME lesions is marked on 6 consecutive slices in an SI joint MRI scan. The maximum score for 2 SI joints on each slice is 8. In addition to these 8 points, a score for intensity (additional 1 point) may be assigned to each SI joint if an "intense" signal [20](#art40718-bib-0020){ref-type="ref"} is detected in any quadrant within the slice. The signal from presacral blood vessels defined a lesion that is scored as intense. Furthermore, a score for depth (additional 1 point) may be assigned to each SI joint if a homogeneous and unequivocal increase in signal extends over a depth of ≥1 cm from the articular surface on each slice, resulting in a maximum score of 12 points per slice. For the assessment using both the ASAS definition and the SPARCC score on the STIR sequence, readers took into account the findings on the T1WSE sequences, looking at both sequences simultaneously.

In the case of disagreement between the 2 readers regarding the presence of radiographic sacroiliitis (based on the modified New York criteria) or a positive MRI result (based on the ASAS definition), a third reader served as adjudicator, and the 2 scores in agreement were considered to be the final score. The positive MRI SPARCC scores from the 2 in agreement were used for further analysis.

Statistical analysis {#art40718-sec-0010}
--------------------

Disease characteristics of patients were recorded using descriptive statistics. We described the MRI scans of SI joints (using the ASAS definition of axial SpA) in different ways. First, we depicted the course of MRI‐detected status (positive or negative readings in the SI joints) at the (2 or 3) available time points, and second, we used a 2 × 2 table to reflect changes in MRI‐detected status. Agreement on the absence or presence of MRI‐detected inflammation was assessed by cross‐tabulation and expressed as Cohen\'s kappa. Cumulative probability plots were used to visualize baseline and 1‐year SPARCC scores, in which patients were grouped according to either positivity or negativity according to the ASAS definition. Subsequently, patients of special interest (i.e., those who had MRI scans that reflected a change in axial SpA status at the 3‐month or 1‐year follow‐up) were described phenotypically (according to the presence of SpA features and other disease characteristics).

Thereafter, we investigated the likelihood of having a positive MRI result at any time point during follow‐up and identified which factors determine ASAS‐defined and MRI‐detected axial SpA positivity in the SI joints. After the analysis of the whole patient group, we repeated this analysis in the subset of patients with inflammatory back pain (IBP) according to the ASAS definition [21](#art40718-bib-0021){ref-type="ref"}. We then looked at the likelihood of having a positive MRI at the 2 follow‐up time points (in all patients and in the subgroup of patients with IBP), taking into account the baseline MRI‐detected status. This was done by using generalized estimating equation (GEE) analysis for binomial outcome variables; MRI‐detected axial SpA was used as the dependent variable, and HLA--B27 status and sex were used as independent explanatory variables. C‐reactive protein (CRP) level was added to the model as a covariate in order to assess the contribution of CRP levels in explaining a positive MRI. The likelihood of a positive MRI result (at 3‐month or 1‐year time points) if the baseline scan was either positive or negative was calculated, taking into account HLA--B27 status and sex. Odds ratios (ORs) from the model were converted into probabilities (likelihood) [22](#art40718-bib-0022){ref-type="ref"}, and 95% confidence intervals (95% CIs) were calculated. Data analysis was performed using Stata version 14 software (StataCorp).

Results {#art40718-sec-0011}
=======

Patient characteristics {#art40718-sec-0013}
-----------------------

In total, 188 patients were included in the current study. Baseline characteristics are described in Table [1](#art40718-tbl-0001){ref-type="table"}. The mean ± SD age of the patients was 31.0 ± 8.2 years, and 38.3% were male. The mean ± SD duration of back pain was 13.2 ± 7.1 months, and 139 patients (74.3%) had ASAS‐defined IBP. Almost half of the patients (48.4%) were HLA--B27 positive.

###### 

Baseline patient characteristics[a](#art40718-note-0002){ref-type="fn"}

  ----------------------------------------------------------------------------------- ------------
  Age at enrollment, mean ± SD years                                                  31.0 ± 8.2
  Male sex                                                                            72 (38.3)
  Symptom duration at first visit, mean ± SD months                                   13.2 ± 7.1
  Good response to NSAIDs                                                             76 (41.3)
  IBP                                                                                 139 (74.3)
  Family history of SpA                                                               96 (51.3)
  Peripheral arthritis                                                                34 (18.2)
  Dactylitis                                                                          15 (8.0)
  Enthesitis                                                                          41 (21.9)
  Uveitis                                                                             16 (8.6)
  IBD                                                                                 17 (9.1)
  Psoriasis                                                                           25 (13.4)
  Elevated CRP level                                                                  35 (18.9)
  HLA--B27 positive                                                                   91 (48.4)
  Radiographically detected sacroiliitis                                              19 (11.1)
  MRI‐detected positive result for axial SpA[b](#art40718-note-0003){ref-type="fn"}   31 (16.5)
  Axial SpA diagnosis[c](#art40718-note-0004){ref-type="fn"}                          74 (39.6)
  ----------------------------------------------------------------------------------- ------------

Except where indicated otherwise, values are the number (%) of patients. NSAIDs = nonsteroidal antiinflammatory drugs; IBP = inflammatory back pain; SpA = spondyloarthritis; IBD = inflammatory bowel disease; CRP = C‐reactive protein; MRI = magnetic resonance imaging.

Based on Assessment of SpondyloArthritis international Society axial SpA criteria.

According to rheumatologist, with a confidence level of ≥7 (rating scale 0--10).

John Wiley & Sons, Ltd

MRI findings {#art40718-sec-0014}
------------

Agreement between the 2 readers regarding the designation of an ASAS‐defined, axial SpA--positive MRI finding was good (κ = 0.85). In 8 of 188 cases (4.3%), adjudication from a third reader was needed, as reader 1 and reader 2 were in disagreement on axial SpA status.

Table [2](#art40718-tbl-0002){ref-type="table"} describes the course of MRI‐detected axial SpA positivity over time. For 122 of the 188 patients (65%), MRI data from all 3 time points were available. For 66 of the 188 patients (35%), MRI was performed at only 2 time points: at baseline and at 3 months for 21 of the 66 patients (32%), and at baseline and at 1 year for 45 patients (68%). In these 3 scenarios, the vast majority of patients (77.1%) had a negative MRI finding at baseline, which had not changed at the follow‐up time point(s). Of the 122 patients who had MRI data available from all 3 time points, persistence of a positive MRI finding was seen in 15 (12.3%), and MRI status fluctuations were seen in 21 (17.2%) over time (i.e., negative--negative--positive results, or positive--positive--negative results, etc.).

###### 

Course of positive MRI results in sacroiliac joints over 1 year[a](#art40718-note-0005){ref-type="fn"}

  MRI results over time                                             No. of patients
  ----------------------------------------------------------------- -----------------
  Patients with available MRI results at baseline/3 months/1 year   122
  −/−/−                                                             86
  +/+/+                                                             15
  −/−/+                                                             7
  +/+/−                                                             7
  −/+/+                                                             3
  +/−/−                                                             2
  +/−/+                                                             1
  −/+/−                                                             1
  Patients with available MRI results at baseline/3 months          21
  −/−                                                               18
  +/+                                                               2
  −/+                                                               1
  Patients with available MRI results at baseline/1 year            45
  −/−                                                               41
  +/+                                                               2
  +/−                                                               2

Positive magnetic resonance imaging (MRI) results for axial spondyloarthritis are represented by +, and negative results by −.

John Wiley & Sons, Ltd

Changes in MRI‐detected axial SpA positivity over time are depicted in Table [3](#art40718-tbl-0003){ref-type="table"}. In contrast to Table [2](#art40718-tbl-0002){ref-type="table"}, data are clustered and shown independently of whether there were available data from a third time point. In 8 of 143 patients (5.6%), a change in axial SpA status was seen at the 3‐month follow‐up. At the 1‐year follow‐up, this proportion was slightly higher at 12.6%. The MRI results in 10 of 138 patients (7.2%) changed from negative at baseline to positive at the 1‐year follow‐up (compared to 5 of 116 patients \[4.3%\] who had a positive result at the 3‐month follow‐up), and 11 of 29 patients (37.9%) with a positive MRI finding at baseline had a negative finding at the 1‐year follow‐up (compared to 3 of 27 patients \[11.1%\] who had a negative result at the 3‐month follow‐up). Thus, patients were more likely to have a negative MRI finding following a positive baseline finding than they were to have a positive finding following a negative baseline finding. Cumulative probability plots (for each of the readers) of baseline and 1‐year SPARCC scores, in which patients were grouped according to either ASAS‐defined axial SpA positivity or negativity, were completed (see Supplementary Figure [1](#art40718-sup-0001){ref-type="supplementary-material"}, on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.40718/abstract>).

###### 

Changes in MRI‐detected axial spondyloarthritis status over 3 months and 1 year[a](#art40718-note-0101){ref-type="fn"}

                          MRI ASAS positive   MRI ASAS negative   Total
  ----------------------- ------------------- ------------------- -------
  3‐month status                                                  
  MRI baseline positive   24                  3                   27
  MRI baseline negative   5                   111                 116
  Total                   29                  114                 143
  1‐year status                                                   
  MRI baseline positive   18                  11                  29
  MRI baseline negative   10                  128                 138
  Total                   28                  139                 167

MRI = magnetic resonance imaging; ASAS = Assessment of SpondyloArthritis international Society.

John Wiley & Sons, Ltd

We reviewed with special interest the disease characteristics of patients who showed changes in MRI‐detected axial SpA status (Table [4](#art40718-tbl-0004){ref-type="table"}). Of the 5 patients whose SpA status changed from negative at baseline to positive at 3 months, 3 patients (60%) were male, and 3 patients (60%) were HLA--B27 positive. One of these patients had radiographically detected sacroiliitis (using the modified New York criteria) at baseline. At 3 months, 2 patients developed a new SpA feature, namely responsiveness to NSAIDs. One patient took NSAIDs at baseline, while 3 patients (60%) took them at 3 months. The 3 patients who had an axial SpA--positive MRI at baseline but had a negative result at the 3‐month follow‐up were HLA--B27--positive men who had been receiving NSAID treatment since baseline (Table [4](#art40718-tbl-0004){ref-type="table"}).

###### 

Disease characteristics of patients with a change in MRI‐detected axial SpA status at 3‐month or 1‐year follow‐ups[a](#art40718-note-0007){ref-type="fn"}

  MRI‐detected axial SpA status         Radiographically detected sacroliitis[b](#art40718-note-0008){ref-type="fn"}   HLA--B27 positive   Age/sex   SpA features at baseline[c](#art40718-note-0009){ref-type="fn"}   SpA features at follow‐up[c](#art40718-note-0009){ref-type="fn"}   CRP level at baseline   CRP level at follow‐up   ASDAS at baseline   ASDAS at follow‐up   Medication at baseline   Medication at follow‐up   SPARCC score at baseline (reader 1/ reader 2)   SPARCC score at follow‐up (reader 1/ reader 2)
  ------------------------------------- ------------------------------------------------------------------------------ ------------------- --------- ----------------------------------------------------------------- ------------------------------------------------------------------ ----------------------- ------------------------ ------------------- -------------------- ------------------------ ------------------------- ----------------------------------------------- ------------------------------------------------
  Baseline negative/ 3‐month positive                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Patient 1                             Yes                                                                            Yes                 19/M      1, 2                                                              Idem                                                               3                       5                        0.8                 --                   --                       --                        0/0                                             5/6
  Patient 2                             No                                                                             No                  38/F      1, 3                                                              Idem                                                               3                       5                        --                  --                   NSAID                    NSAID                     1/1                                             2/2
  Patient 3                             No                                                                             Yes                 25/M      2, 8                                                              Idem + 9                                                           6                       4                        1.6                 --                   --                       NSAID                     0/0                                             10/7
  Patient 4                             No                                                                             No                  29/F      1                                                                 Idem                                                               3                       1                        0.9                 --                   --                       --                        0/0                                             9/12
  Patient 5                             No                                                                             Yes                 26/M      1, 2                                                              Idem + 9                                                           3                       3                        1.6                 --                   --                       NSAID                     0/0                                             5/5
  Baseline positive/ 3‐month negative                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Patient 6                             Yes                                                                            Yes                 21/M      1, 9                                                              Idem                                                               6                       14                       1.4                 --                   NSAID                    NSAID                     3/5                                             0/3
  Patient 7                             No                                                                             Yes                 32/M      1, 6, 9                                                           Idem                                                               3                       4                        3.8                 --                   NSAID                    NSAID                     2/4                                             0/0
  Patient 8                             No                                                                             Yes                 31/M      1, 6, 8, 9                                                        Idem                                                               9                       2                        3.4                 --                   NSAID                    NSAID                     2/2                                             0/0
  Baseline negative/ 1‐year positive                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Patient 9                             No                                                                             Yes                 21/F      1, 2, 5, 9                                                        Idem                                                               3                       3                        2.2                 2.9                  NSAID                    NSAID                     0/0                                             4/3
  Patient 10                            Yes                                                                            Yes                 33/M      1, 4                                                              Idem + 9                                                           3                       3                        0.9                 2.3                  --                       NSAID                     0/0                                             5/6
  Patient 11                            Yes                                                                            Yes                 19/M      1, 2                                                              Idem                                                               3                       1                        0.8                 0.4                  --                       NSAID                     0/0                                             16/18
  Patient 12                            No                                                                             Yes                 31/M      1,2                                                               Idem                                                               3                       3                        2.4                 2.4                  NSAID                    NSAID                     0/2                                             2/3
  Patient 13                            No                                                                             Yes                 32/M      1                                                                 Idem                                                               13                      9                        3.0                 3.2                  NSAID                    NSAID                     0/0                                             3/2
  Patient 14                            No                                                                             Yes                 19/F      2                                                                 Idem                                                               4                       1                        3.3                 1.2                  NSAID                    NSAID                     0/0                                             2/2
  Patient 15                            No                                                                             No                  32/F      1, 2, 6, 9                                                        Idem                                                               1                       1                        2.7                 --                   NSAID                    NSAID                     1/0                                             5/5
  Patient 16                            No                                                                             Yes                 25/M      2, 8                                                              Idem + 1, 7, 9                                                     6                       3                        1.6                 --                   --                       NSAID                     0/0                                             10/7
  Patient 17                            Yes                                                                            Yes                 35/F      9                                                                 Idem                                                               3                       10                       2.5                 --                   --                       NSAID                     1/0                                             14/11
  Patient 18                            No                                                                             No                  29/F      1                                                                 Idem                                                               3                       1                        0.9                 1.0                  --                       NSAID                     0/0                                             13/16
  Baseline positive/ 1‐year negative                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Patient 19                            No                                                                             No                  43/F      1, 6                                                              Idem + 5                                                           1                       1                        1.4                 1.1                  --                       --                        3/2                                             0/0
  Patient 20                            Yes                                                                            Yes                 29/F      1                                                                 Idem + 9                                                           1                       1                        1.6                 1.4                  NSAID                    NSAID + anti‐TNF          14/14                                           0/0
  Patient 21                            No                                                                             Yes                 31/M      1, 6, 8, 9                                                        Idem + 7                                                           9                       1                        3.4                 0.8                  NSAID                    NSAID                     2/2                                             0/0
  Patient 22                            No                                                                             No                  40/F      1                                                                 Idem + 4, 9                                                        4                       4                        2.1                 3.7                  --                       Anti‐TNF                  8/8                                             0/0
  Patient 23                            Yes                                                                            Yes                 22/M      ‐                                                                 1, 2, 9                                                            3                       3                        3.1                 2.7                  NSAID                    NSAID                     9/13                                            1/0
  Patient 24                            No                                                                             Yes                 32/M      1, 6, 9                                                           Idem + 2                                                           3                       3                        3.8                 ‐                    NSAID                    NSAID                     2/4                                             0/0
  Patient 25                            No                                                                             Yes                 33/M      1, 8, 9                                                           Idem                                                               23                      1                        2.9                 1.0                  NSAID                    Anti‐TNF                  7/5                                             0/0
  Patient 26                            No                                                                             No                  46/M      1, 9                                                              Idem                                                               4                       4                        2.7                 1.6                  NSAID                    NSAID                     4/2                                             1/0
  Patient 27                            Yes                                                                            Yes                 24/F      2, 5, 6                                                           Idem + 1, 9                                                        3                       3                        3.0                 1.0                  NSAID                    NSAID + anti‐TNF          46/44                                           0/0
  Patient 28                            Yes                                                                            Yes                 42/M      6, 9                                                              Idem                                                               1                       1                        3.0                 1.0                  NSAID                    NSAID                     10/9                                            0/0
  Patient 29                            Yes                                                                            Yes                 26/M      1, 2                                                              Idem                                                               2                       2                        2.0                 2.3                  --                       NSAID                     18/16                                           2/0

Except where indicated otherwise, characteristics are recorded at baseline. Follow‐up data were obtained at either 3 months (patients 1--8) or 1 year (patients 9--29). MRI = magnetic resonance imaging; CRP = C‐reactive protein; ASDAS = ankylosing spondylitis disease activity score; SPARCC = Spondyloarthritis Research Consortium of Canada system.

Based on the modified New York criteria.

Spondyloarthritis (SpA) characteristics are numerically represented. 1 = inflammatory back pain; 2 = family history of SpA; 3 = uveitis; 4 = irritable bowel disease; 5 = psoriasis; 6 = enthesitis; 7 = dactylitis; 8 = peripheral arthritis; 9 = nonsteroidal antiinflammatory drug (NSAID) responsiveness; idem = same features as at baseline.

John Wiley & Sons, Ltd

Of the 10 patients who were newly MRI‐positive for axial SpA at the 1‐year follow‐up, 5 (50%) were male, and 8 (80%) were HLA--B27 positive. Radiographically detected sacroiliitis was present in 3 patients (30%). At the 1‐year time point, 2 of these 10 patients had developed new SpA features that were not present at baseline (patient 10: NSAID responsiveness; patient 16: NSAID responsiveness, inflammatory back pain, and dactylitis) (Table [4](#art40718-tbl-0004){ref-type="table"}). All 10 patients were taking NSAIDs at the 1‐year follow‐up (versus 50% at baseline), and there were no patients receiving anti‐TNF treatment in this group. Of the 11 patients that had a positive baseline MRI result followed by a negative result at the 1‐year follow‐up, the majority were male (64%), HLA--B27 positive (73%), and had developed new SpA features (55%). In this group, between baseline and the 1‐year follow‐up, anti‐TNF therapy had been added to the treatment regimen of 4 patients, and an NSAID had been added for 1 patient.

Overall, when comparing SPARCC scores assigned by the 2 readers, only modest differences were observed, suggesting a high level of agreement (Table [4](#art40718-tbl-0004){ref-type="table"}). Approximately half of the patients who had negative MRI results for axial SpA and later had positive results (either at 3 months or 1 year) also had marginally positive SPARCC scores at the same time point, while the remaining patients had evidently positive SPARCC scores (as high as 18 in 1 patient). Patients who were initially ASAS positive but became negative after 1 year had mostly low SPARCC scores at baseline, with a few exceptions. Four patients from this group had started receiving anti‐TNF therapy by the 1‐year follow‐up, at which time all 4 showed a notable decrease in SPARCC scores.

Factors determining a positive MRI {#art40718-sec-0015}
----------------------------------

According to the GEE analysis, both HLA--B27 positivity (OR 2.36 \[95% CI 1.09--5.12\], *P* = 0.029) and male sex (OR 5.63 \[95% CI 2.58--12.27\], *P* \< 0.001) were independent determinants of the likelihood of a positive MRI at any time point. Figure [1](#art40718-fig-0001){ref-type="fig"} displays the effects of HLA--B27 and sex in an absolute manner. The likelihood of an axial SpA--positive MRI finding in HLA--B27--negative women with chronic back pain was only 7%, whereas in HLA--B27--positive men it was 43% (HLA--B27--positive women 6%, HLA--B27--negative men 14%). In men, HLA--B27 status had a significant impact on the likelihood of having a positive MRI at any time point (OR 4.54 \[95% CI 1.50--13.79\], *P* = 0.008), whereas this impact was not observed in women (OR 0.84 \[95% CI 0.23--3.12\], *P* = 0.800). The influence of CRP levels on axial SpA status was investigated in all models, but correcting for CRP levels produced only minor changes, and therefore only uncorrected data are shown. Only minor differences were seen between patients with chronic back pain and those with IBP according to the ASAS definition (data not shown).

![Likelihood of a positive magnetic resonance imaging result at any time point (baseline, 3 months, and 1 year) in chronic back pain patients investigated for axial spondyloarthritis. HLA--B27 status and sex were used as variables.](ART-71-382-g001){#art40718-fig-0001}

Likelihood of a positive MRI during follow‐up {#art40718-sec-0016}
---------------------------------------------

The likelihood of an MRI‐detected axial SpA positive result at 3 months or 1 year, according to the baseline MRI status, was considered. Both HLA--B27 status (OR 2.41 \[95% CI 0.94--6.18\], *P* = 0.067) and baseline MRI status (OR 43.89 \[95% CI 17.59--109.52\], *P* \< 0.001) independently contributed to the likelihood of a positive MRI at follow‐up. Other factors contributing to a positive MRI over time included male sex (OR 2.54 \[95% CI 1.01--6.39\], *P* = 0.048) and baseline MRI positivity (OR 36.04 \[95% CI 14.42--90.08\], *P* \< 0.001). Once again, only minor (not significant) differences were observed between chronic back pain patients and IBP patients (data not shown).

In Figure [2](#art40718-fig-0002){ref-type="fig"}, the likelihood of a positive MRI in relation to baseline MRI and HLA--B27 status and sex is depicted. In an HLA--B27--negative patient with a negative baseline MRI, the likelihood of a positive MRI at follow‐up was negligible (1.5%) (Figure [2](#art40718-fig-0002){ref-type="fig"}A). On the contrary, in an HLA--B27--positive patient with a positive baseline MRI, the likelihood was 73%. In patients with a positive baseline MRI, HLA--B27 status did not influence the likelihood of a positive MRI at any follow‐up time point (OR 0.65 \[95% CI 0.14--2.96\], *P* = 0.582). However, in patients with a negative baseline MRI, HLA--B27 positivity had a significant effect on the likelihood of a positive MRI at follow‐up (OR 8.12 \[95% CI 1.65--40.11\], *P* = 0.010).

![Likelihood of a positive magnetic resonance imaging result at 3‐month or 1‐year follow‐up in chronic back pain patients investigated for axial spondyloarthritis. **A,** Baseline MRI result and HLA--B27 status were used as variables. **B,** Baseline MRI result and sex were used as variables.](ART-71-382-g002){#art40718-fig-0002}

For a male or female patient with a positive baseline MRI, the likelihood of having a positive MRI at 3 months or 1 year was 75%; however, the likelihood was only 2.8% for a female patient with a negative baseline MRI and 12% for a male patient with a negative baseline MRI (Figure [2](#art40718-fig-0002){ref-type="fig"}B). In patients with a negative baseline MRI, sex significantly affected the likelihood of having a positive MRI at follow‐up (OR 4.67 \[95% CI 1.41--15.44\], *P* = 0.01), though this was not true for patients with a positive baseline MRI (OR 0.96 \[95% CI 0.20--4.54\], *P* = 0.959). MRI scans of SI joints in patients with axial SpA status changes over 1 year are shown in Supplementary Figure [2](#art40718-sup-0001){ref-type="supplementary-material"} (available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.40718/abstract>).

Discussion {#art40718-sec-0017}
==========

In the present study, 83.5% of patients (157 of 188) with chronic back pain and in whom axial SpA was suspected had a negative MRI at baseline. Only 7.6% of these patients (12 of 157) had a positive MRI at either follow‐up time point. Twelve of the 31 patients (38.7%) with a positive MRI at baseline had a negative MRI at follow‐up. Although reversals in axial SpA status are apparent in both directions, relatively more patients who had a positive baseline MRI result later had a negative MRI result (11.1% at 3 months and 37.9% at 1 year) than those who had a negative baseline MRI result and later had a positive MRI result (4.3% at 3 months and 7.2% at 1 year). Nevertheless, it is important to note that 36% of the patients who had negative findings after 1 year had begun anti‐TNF therapy, which is known to decrease visible inflammation in the SI joints [16](#art40718-bib-0016){ref-type="ref"}.

This study showed that MRI‐detected axial SpA positivity at baseline appears to strongly influence the chance of positive SI joint MRI results in the future. If the baseline MRI result was positive, the likelihood that the MRI result would be positive again at 3 months or 1 year was very high (75%). The usefulness of repeated negative MRI in terms of diagnostic yield is low, but there are different risks related to sex and HLA--B27 status.

In patients who had a negative baseline MRI result, HLA--B27 status had a significant effect on the likelihood of a positive MRI at follow‐up. In HLA--B27--negative patients with a negative MRI result at baseline, sacroiliitis at follow‐up could be excluded with a high level of confidence: the likelihood of a positive MRI result at follow‐up was only 1.5%. In HLA--B27--positive patients with a negative MRI result at baseline, the likelihood of a positive MRI result at 3 months or 1 year was still low, though somewhat higher (11%). Of course, we can debate the clinical relevance of this small difference in terms of percentage and, in general, the chances of MRI positivity at follow‐up were very low when the baseline MRI result was negative. However, if a clinical suspicion of axial SpA remains (i.e., if a patient develops other SpA features), it may be worthwhile to consider repeating an MRI scan in HLA--B27--positive patients. Likewise, there was a statistically significant difference between male and female patients who had a negative baseline MRI result, specifically that male patients more frequently had a positive MRI result at follow‐up (12% of men versus 3% of women). Interpretation of MRI findings should always be made in the context of all clinical and laboratory results (e.g., other SpA features that enhance diagnostic confidence) and other available imaging parameters. Additionally, other MRI findings (e.g., the presence of structural lesions) can be supportive in the diagnostic process. However, in this group of patients with short symptom duration, the frequency of structural changes in SI joints was relatively low and discriminated between patients with and without axial SpA only if ≥5 structural lesions (especially erosions and fatty lesions) were present [11](#art40718-bib-0011){ref-type="ref"}. This suggests that at this phase of the disease, BME is the feature with the best predictive value.

Van Onna et al performed a 2‐year follow‐up study [23](#art40718-bib-0023){ref-type="ref"}, in which they recorded MRI status changes in 15% of their patients with recent‐onset IBP. These findings were similar to our own, although follow‐up time was considerably shorter in our study. On the other hand, our study included substantially more patients, and we used 2 validated scoring methods. Also in accordance with our results, their data showed that more patients had a negative follow‐up result after a positive baseline result, compared to patients who developed a positive result after a negative baseline result (30% versus 15%, respectively, based on 1‐year or 2‐year follow‐up MRI). Additionally, they found that male sex and HLA--B27 positivity were predictive of a positive MRI result at follow‐up, which is consistent with our finding that these factors independently determine the likelihood of a positive MRI result at any time point. HLA--B27--positive male patients with chronic back pain have the highest chance of a positive MRI result at any time.

Other studies have investigated the natural history of MRI‐detected BME in individuals with suspected axial SpA. Sengupta et al concluded that repeated MRI scans within a 12‐week period should be considered only for HLA--B27--positive men who fulfill the ASAS IBP criteria, since there were no HLA--B27--negative patients in their study who had a negative MRI result followed by a positive MRI result [24](#art40718-bib-0024){ref-type="ref"}. Although their study included a considerably smaller group of patients, the data are consistent with our findings that HLA--B27 positivity determines the likelihood of a positive MRI result. Marzo‐Ortega et al also reported a higher chance of a positive MRI result at 1 year in untreated patients with early IBP who were HLA--B27 positive [25](#art40718-bib-0025){ref-type="ref"}.

Regarding sex differences, ankylosing spondylitis (AS) has historically been considered a predominantly male disease, but it has been reported that 46% of patients diagnosed since 1990 were female, compared to 10% in 1960 [26](#art40718-bib-0026){ref-type="ref"}. This suggests that perceived male predominance in AS and axial SpA may be caused (at least in part) by a missed AS diagnosis among women (especially prior to 1990); data now suggest that the percentage of female patients with nonradiographic axial SpA and AS is substantial. Another reason for the higher male:female ratio in AS may be that men develop radiographic sacroiliitis at a higher rate than women. This is also in accordance with our findings that male patients are more likely to have a positive MRI result at any time point, which is a predictor of development of radiographic sacroiliitis [9](#art40718-bib-0009){ref-type="ref"}.

Another issue we considered in our study is timing, specifically at what time point to repeat an MRI scan in the case of persistent suspected axial SpA. We looked at the 3‐month and 1‐year follow‐ups, and at both time points the additional value is very limited. Given the low diagnostic yield (and taking into account costs and feasibility), MRI should not be routinely repeated after 3 months or 1 year. Two‐year data on the SPACE cohort will be available in the future and will provide information on a longer period of time.

In general, MRI has become an important tool in the evaluation of patients who have (or may have) axial SpA. Relevant improvements in the field have taken place as a result, such as the standardization of imaging protocols and the development and validation of standardized descriptions of lesions. These descriptions pertain not only to inflammatory lesions but to structural lesions (e.g., fatty lesions, erosions, sclerosis, and ankylosis). MRI has the unique benefit of providing visualization of both inflammatory and structural lesions via one imaging technique. Additionally, it is hypothesized that assessment for structural lesions could enhance sensitivity and/or specificity, which might be helpful when a diagnosis is initially unclear. Research on the incremental value of including structural lesions is ongoing.

In terms of methodology, the fact that we repeated MRI in all patients irrespective of diagnosis is an important strength of our study, compared to studies that conducted scans in a select population within their patient groups. Moreover, our follow‐up was quite comprehensive and avoided the unintentional bias that could occur by excluding patients with a low likelihood of axial SpA. Another strength of our study is our scoring process that involved 2 readers and adjudication from a third reader in the case of discrepancy, which adds to the credibility of the findings. Moreover, the fact that we used 2 well‐validated scoring methods (ASAS criteria and SPARCC scoring system) provides additional insight. On the other hand, limitations of the current study include the relatively short duration of follow‐up and the fact that we could not compare these findings to an external standard. Diagnosis of axial SpA was influenced by MRI findings and could lead to circular reasoning. Moreover, we lacked validation from another imaging technique such as low‐dose computed tomography or from histology. Prospective evaluation over a sufficient time frame with a longer follow‐up should enhance confidence in the diagnosis of this sometimes slow‐to‐evolve disease.

In conclusion, ASAS‐defined, MRI‐detected axial SpA status changes were seen in a minority of the patients in the SPACE cohort, and both changes from negative to positive and from positive to negative occurred. A very small percentage of patients had a positive MRI result at follow‐up after having a negative result at baseline (4.3% at 3 months and 7.2% at 1 year), which indicates that the diagnostic usefulness of repeating an MRI of the SI joints at 3 months or 1 year is very limited. Relatively more patients had a negative MRI result after having a positive result at baseline (37.9% after 1 year), and the resolution of inflammation was partly caused by the use of anti‐TNF therapy. Male sex and HLA--B27 positivity independently determined the likelihood of a positive MRI result at any time point, while MRI‐detected axial SpA status at baseline strongly predicted status at follow‐up.
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